Clinical Scorecard: Biologics Commonly Used in Cutaneous Crohn Disease
At a Glance
| Category | Detail |
|---|---|
| Condition | Cutaneous Crohn Disease |
| Key Mechanisms | Granulomatous skin manifestation associated with Crohn disease. |
| Target Population | Pediatric and adult patients with cutaneous Crohn disease. |
| Care Setting | Dermatology clinics across nine US academic centers. |
Key Highlights
- 81% of patients were female.
- 70% had intestinal Crohn disease at the time of CCD diagnosis.
- Genital involvement was the most common cutaneous presentation, reported in 44% of patients.
- Tumor necrosis factor alpha inhibitors were the most commonly prescribed agents, used in 85% of treated patients.
- Study limitations include retrospective design and heterogeneous data collection.
Guideline-Based Recommendations
Diagnosis
- Diagnosis requires clinical and histopathologic findings consistent with Delphi consensus criteria.
Management
- Biologic or small-molecule inhibitor therapy was used in 82% of patients.
Monitoring & Follow-up
- Outcomes categorized as complete clearance, partial clearance, no effect, or worsening based on clinical documentation.
Risks
- Study limitations include uncontrolled design and frequent use of combination therapy.
Patient & Prescribing Data
57 patients with cutaneous Crohn disease identified from 2000 to 2020.
Most patients received combination therapy; single-agent therapy was uncommon.
Clinical Best Practices
- Consider tumor necrosis factor alpha inhibitors as first-line therapy.
- Monitor for treatment efficacy and adjust therapy as needed.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
